TRIB2 and cancer: Although TRIB2 has been reported to modulate p38,34 p38 inhibition did not abrogate the anisomycin‐induced phosphorylation of HDAC2 in ESCC cells, suggesting that the effect of TRIB2 on the MAPK pathway might be cancer‐dependent.